

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (original) An eye-drop vaccine for therapeutic immunization of a mammal comprising an active agent selected from the group consisting of Copolymer 1, a Copolymer 1-related peptide, and a Copolymer 1-related polypeptide.

2. (original) An eye-drop vaccine according to claim 1 for treating neuronal degeneration caused by an injury, disease, disorder or condition in the central nervous system (CNS) or peripheral nervous system (PNS), for preventing or inhibiting neuronal secondary degeneration which may otherwise follow a primary injury in the CNS, for promoting nerve regeneration in the CNS or in the PNS after injury or disease, disorder or condition or for protecting CNS and PNS cells from glutamate toxicity.

3. (original) An eye-drop vaccine according to claim 2, wherein said injury is spinal cord injury, blunt trauma, penetrating trauma, brain coup or contrecoup, hemorrhagic stroke, or ischemic stroke.

4. (original) An eye-drop vaccine according to claim 2, wherein said disease, disorder or condition is a senile dementia including Alzheimer's disease, a Parkinsonian

syndrome including Parkinson's disease, facial nerve (Bell's) palsy, Huntington's chorea, a motor neuron disease including amyotrophic lateral sclerosis, a prion disease including Creutzfeldt-Jakob disease, Alper's disease, Batten disease, Cockayne syndrome, Lewy body disease, status epilepticus, carpal tunnel syndrome, intervertebral disc herniation, vitamin deficiency such as vitamin B deficiency, seizure disorders such as epilepsy, psychotic disorders such as schizophrenia and anxiety, amnesia, hyperalgesia, oxidative stress, opiate tolerance and dependence, an autoimmune disease, a peripheral neuropathy associated with a disease such as amyloid polyneuropathy, diabetic neuropathy, uremic neuropathy, porphyric polyneuropathy, hypoglycemia, Sjogren-Larsson syndrome, acute sensory neuropathy, chronic ataxic neuropathy, biliary cirrhosis, primary amyloidosis, obstructive lung diseases, acromegaly, malabsorption syndromes, polycythemia vera, IgA and IgG gammopathies, complications of various drugs such as nitrofurantoin, metronidazole, isoniazid and toxins such as alcohol or organophosphates, Charcot-Marie-Tooth disease, ataxia telangiectasia, Friedreich's ataxia, adrenomyeloneuropathy, giant axonal neuropathy, Refsum's disease, Fabry's disease, lipoproteinemia, non-arteritic optic neuropathy, age-related macular degeneration, a retinal disorder such as retinal degeneration, or a disease associated with abnormally elevated intraocular pressure such as glaucoma.

5. (original) An eye-drop vaccine according to claim 4, wherein said autoimmune disease is multiple sclerosis.

6. (original) An eye-drop vaccine according to claim 1, wherein said vaccine comprises the active agent without an adjuvant.

7. (original) An eye-drop vaccine according to claim 1, wherein said vaccine comprises the active agent with a soluble adjuvant.

8. (original) An eye-drop vaccine according to claim 7, wherein said soluble adjuvant is a cytokine.

9. (original) An eye-drop vaccine according to claim 8, wherein said cytokine is IL-2, IL-12, IFN- $\gamma$  or GM-CSF.

10. (currently amended) An eye-drop vaccine according to ~~any one of claims 1 to 9~~, wherein said active agent is Copolymer 1.

11. (currently amended) An eye-drop vaccine according to ~~any one of claims 1 to 9~~, wherein said active agent is a Copolymer 1-related peptide or a Copolymer 1-related polypeptide.

12. (original) An eye-drop vaccine according to claim 1, for administration at a frequency of at least once every day or every alternate day to a multiple sclerosis patient.

13. (original) An eye-drop vaccine according to claim 1, for administration periodically at a frequency of at least once every seven days, to at least once every month to at least once every 2-3 months, to a non-multiple sclerosis patient.

14. (original) An eye-drop vaccine according to claim 13, for administration to a glaucoma patient.

Claims 15-29 (cancelled)

30. (original) A method of therapeutic immunization for treating neuronal degeneration caused by an injury, disease,

disorder or condition in the central nervous system (CNS) or peripheral nervous system (PNS), for preventing or inhibiting neuronal secondary degeneration which may otherwise follow a primary injury in the CNS, for promoting nerve regeneration in the CNS or in the PNS after an injury, disease, disorder or condition or for protecting CNS and PNS cells from glutamate toxicity, which comprises immunizing an individual in need with an eye-drop vaccine comprising an active agent selected from the group consisting of Copolymer 1, a Copolymer 1-related peptide, and a Copolymer 1-related polypeptide, in an amount effective to treat, prevent or inhibit said neuronal degeneration caused by said injury, disease, disorder or condition in the individual.

31. (original) A method according to claim 30, wherein said injury is spinal cord injury, blunt trauma, penetrating trauma, brain coup or contrecoup, hemorrhagic stroke, or ischemic stroke.

32. (original) A method according to claim 30, wherein said disease is a senile dementia including Alzheimer's disease, a Parkinsonian syndrome including Parkinson's disease, facial nerve (Bell's) palsy, Huntington's chorea, a motor neuron disease including amyotrophic lateral sclerosis, a prion disease including Creutzfeldt-Jakob disease, Alper's disease, Batten disease, Cockayne syndrome, Lewy body disease, status epilepticus, carpal tunnel syndrome, intervertebral disc herniation, vitamin deficiency such as vitamin B deficiency, epilepsy, amnesia, anxiety, hyperalgesia, psychosis, seizures, oxidative stress, opiate tolerance and dependence, an autoimmune disease, or a peripheral neuropathy associated with a disease such as amyloid polyneuropathy, diabetic neuropathy, uremic neuropathy, porphyric

polyneuropathy, hypoglycemia, Sjogren-Larsson syndrome, acute sensory neuropathy, chronic ataxic neuropathy, biliary cirrhosis, primary amyloidosis, obstructive lung diseases, acromegaly, malabsorption syndromes, polycythemia vera, IgA and IgG gammopathies, complications of various drugs such as nitrofurantoin, metronidazole, isoniazid and toxins such as alcohol or organophosphates, Charcot-Marie-Tooth disease, ataxia telangiectasia, Friedreich's ataxia, adrenomyeloneuropathy, giant axonal neuropathy, Refsum's disease, Fabry's disease, lipoproteinemia, non-arteritic optic neuropathy, age-related macular degeneration, a retinal disorder such as retinal degeneration, or a disease associated with abnormally elevated intraocular pressure such as glaucoma.

33. (original) A method according to claim 32, wherein said autoimmune disease is multiple sclerosis.

34. (original) A method according to claim 30, which comprises immunization with the active agent without an adjuvant.

35. (original) A method according to claim 30, which comprises immunization with the active agent with a soluble adjuvant.

36. (original) A method according to claim 35, wherein said soluble adjuvant is a cytokine.

37. (original) A method according to claim 36, wherein said cytokine is IL-2, IL-12, IFN- $\gamma$  or GM-CSF.

38. (original) A method according to claim 30, wherein said active agent is Copolymer 1.

39. (original) A method according to claim 30, wherein said active agent is a Copolymer 1-related peptide or a Copolymer 1-related polypeptide.

40. (original) A method according to claim 30, wherein said vaccine is administered at a frequency of at least once every day or every alternate day to a multiple sclerosis patient.

41. (original) A method according to claim 30, wherein said vaccine is administered periodically at a frequency of at least once every seven days, to at least once every month to at least once every 2-3 months, to a non-multiple sclerosis patient.

42. (original) A method of therapeutic immunization of a glaucoma patient which comprises administering to the patient an eye-drop vaccine comprising Copolymwe 1 in an amount effective to treat glaucoma in said patient.

43. (original) A method for reducing neuronal degeneration caused by the neurodegenerative effects of a disease, or for reducing secondary neuronal degeneration that follows the primary neuronal degeneration of an injury, in the central nervous system (CNS) or peripheral nervous system (PNS) of an individual in need thereof, which comprises immunizing the individual in need with an eye-drop vaccine comprising an active agent selected from the group consisting of Copolymer 1, a Copolymer 1-related peptide, and a Copolymer 1-related polypeptide, in an amount effective to reduce said neuronal degeneration caused by injury or disease in said individual.